Document is current
Any future updates will be listed below
-
Authors
Mohebi, Reza
Liu, Yuxi
Hansen, Michael K.
Yavin, Yshai
Sattar, Naveed
Pollock, Carol A.
Butler, Javed
Jardine, Meg
Masson, Serge
Heerspink, Hiddo J. L.
Januzzi Jr, James L.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02065791 at ClinicalTrials.govDocuments that mention this clinical trial
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease
https://doi.org/10.1161/circulationaha.120.048740
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial
https://doi.org/10.2215/cjn.08980621
Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
https://doi.org/10.1007/s13300-020-00968-x
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria (Results)
https://doi.org/10.2215/cjn.15260920
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy
https://doi.org/10.1007/s13300-020-00953-4
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
https://doi.org/10.1080/14740338.2019.1626823
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
https://doi.org/10.1681/asn.2020050723
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
https://doi.org/10.1161/strokeaha.120.031623
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
https://doi.org/10.1681/asn.2019111168
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2
https://doi.org/10.2215/cjn.10140620
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
https://doi.org/10.1186/s12933-023-01916-2
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
https://doi.org/10.1161/circulationaha.123.065251
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
https://doi.org/10.1136/bmjopen-2017-018097
- License Information
-
More Information
Article History
Received: 11 March 2023
Accepted: 3 July 2023
First Online: 12 July 2023
Declarations
:
: Local ethics committees approved all study procedures for the CREDENCE trial and subsequent analyses. Consent was obtained from all study participants.
: Not applicable.
: Drs. Michael Hansen and Yshai Yavin are full-time employees of Janssen Research & Development, LLC. Dr. Januzzi is supported by the Hutter Family Professorship; is a Trustee of the American College of Cardiology; is a board member of Imbria Pharmaceuticals and a Director at Jana Care; has received grant support from Abbott Diagnostics, Applied Therapeutics, Innolife, and Novartis; has received consulting income from Abbott Diagnostics, Boehringer Ingelheim, Janssen, Novartis, Roche Diagnostics; and participates in clinical endpoint committees/data safety monitoring boards for AbbVie, Siemens, Takeda, and Vifor. The rest of authors have no disclosure.
